Welcome to our dedicated page for Cellectis news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis stock.
Cellectis S.A. develops gene-edited cell and gene therapies as a clinical-stage biotechnology company. Its recurring news centers on allogeneic CAR T immunotherapies in oncology, including off-the-shelf, gene-edited CAR T-cell product candidates, and on broader gene therapy research using its gene-editing platform and in-house manufacturing capabilities.
Company updates commonly cover clinical and partner-program developments for candidates such as lasme-cel, eti-cel and cema-cel; TALE-based and epigenetic editing research; financial results and business updates; collaborations and license arrangements; and monthly disclosures of share capital and voting rights for its Euronext Growth listing alongside its Nasdaq-listed ADS trading under CLLS.
Cellectis (NASDAQ:CLLS), a clinical-stage biotechnology company focused on gene-editing therapies, held its shareholders general meeting on June 26, 2025. With approximately 57% of voting rights exercised, shareholders approved 25 out of 26 resolutions.
The meeting resulted in significant board changes: Mr. André Muller, current CEO of Idorsia Pharmaceuticals, was appointed as a new board member, while Mr. Pierre Bastid resigned and Mr. Axel-Sven Malkomes' term expired. Muller brings extensive experience from his roles at Idorsia, Actelion Pharmaceuticals, and Pierre Fabre SA.
Cellectis (NASDAQ: CLLS), a clinical-stage biotechnology company focused on gene-editing and cell and gene therapies, has announced its upcoming annual shareholders general meeting. The meeting is scheduled for June 26, 2025, at 2:30 p.m. CET and will be held at the Biopark auditorium in Paris, France. Shareholders can access detailed information about the meeting agenda and participation modalities through the company's website.
Cellectis (CLLS) has released its monthly share capital and voting rights report as of April 30, 2025. The company reported a total of 100,290,220 shares in its capital structure, with 89,075,490 total voting rights. This disclosure is made in accordance with Article 223-16 of the General Regulation of the French financial markets authority, as the company is listed on Euronext Growth.
Cellectis unveiled groundbreaking research data on gene-editing technologies at the upcoming Society of Gene and Cell Therapy annual meeting in New Orleans (May 13-17, 2025). The company presented two significant innovations:
1. TALEN-Mediated Non-viral Transgene Insertion:
- Successfully combined TALEN gene editing with non-viral delivery methods
- Demonstrated high efficiency in T-cells and blood stem cells
- Showed better cell fitness and stability compared to traditional viral methods
- Addresses challenges of viral methods like manufacturing limits and toxicity risks
2. TALE Base Editors (TALEB) Development:
- Created new method for precise C-to-T DNA conversion
- Achieved efficient editing without DNA strand damage
- Showed no detectable off-target editing in primary cells
- Developed system to assess editing efficiency across different sequences
These breakthroughs could advance treatments for cancer, autoimmune diseases, and genetic disorders. The complete research data will be available on Cellectis' website when the event begins.
Cellectis (CLLS) has released its monthly share capital and voting rights report as of March 31, 2025. The company reported a total of 100,290,078 shares in its capital structure, with 89,046,759 total voting rights. This disclosure complies with Article 223-16 of the General Regulation of the French financial markets authority for companies listed on Euronext Growth.
Cellectis (CLLS) reported its Q4 and full year 2024 financial results, highlighting significant progress in its clinical programs and strategic partnerships. The company maintains a strong cash position of $264 million, providing runway into mid-2027.
Key pipeline updates include:
- UCART22 Phase 1 data and development strategy expected in Q3 2025, with FDA granting Orphan Drug and Rare Pediatric Disease Designations
- UCART20x22 Phase 1 study in NHL ongoing with readout expected late 2025
- Three active programs in collaboration with AstraZeneca
Notable corporate developments include AstraZeneca's $140 million additional equity investment and the completion of European Investment Bank financing drawdown of €40 million. The company has deprioritized UCART123 development to focus on BALLI-01 and NATHALI-01 studies.
Cellectis (NASDAQ: CLLS), a clinical-stage biotechnology company focused on gene-editing platforms for cell and gene therapies, has scheduled its fourth quarter and full year 2024 financial results announcement for March 13, 2025, after US market close.
The company will host an investor conference call and webcast on March 14, 2025, at 8:00 AM ET / 1:00 PM CET to discuss the financial results and provide business updates. Investors can access the call through domestic (+1-800-225-9448) or international (+1-203-518-9708) dial-in numbers using Conference ID: CLLS24.